Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director John Johnson Sells 107,500 Shares

Key Points

• John Johnson, a director at Xeris Biopharma, sold 107,500 shares of the company's stock for approximately $786,900, reducing his holdings by 11.42%.
• Xeris Biopharma reported a net revenue of $67.71 million for the last quarter, exceeding analyst expectations and achieving earnings per share of ($0.01), which was better than the forecast of ($0.03).
• Several analysts have recently upgraded their ratings on Xeris Biopharma's stock, with the company receiving a consensus rating of "Buy" and a price target averaging around $6.58.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) Director John Johnson sold 107,500 shares of the firm's stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $7.32, for a total transaction of $786,900.00. Following the transaction, the director owned 833,483 shares in the company, valued at $6,101,095.56. This represents a 11.42% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Xeris Biopharma Stock Performance

Xeris Biopharma stock traded up $0.38 during trading hours on Friday, hitting $7.68. 3,517,509 shares of the stock were exchanged, compared to its average volume of 2,576,892. Xeris Biopharma Holdings, Inc. has a 12 month low of $2.48 and a 12 month high of $7.72. The business's 50-day moving average is $5.16 and its two-hundred day moving average is $4.68. The stock has a market capitalization of $1.24 billion, a P/E ratio of -36.57 and a beta of 0.65.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.02. The firm had revenue of $67.71 million during the quarter, compared to analyst estimates of $64.58 million. On average, equities analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. NewEdge Advisors LLC bought a new stake in shares of Xeris Biopharma during the 4th quarter worth about $34,000. Raymond James Financial Inc. acquired a new position in shares of Xeris Biopharma in the 4th quarter valued at approximately $45,000. Two Sigma Advisers LP bought a new stake in shares of Xeris Biopharma during the 4th quarter valued at approximately $47,000. Aquatic Capital Management LLC bought a new stake in shares of Xeris Biopharma during the 4th quarter valued at approximately $50,000. Finally, Wealth Enhancement Advisory Services LLC grew its holdings in Xeris Biopharma by 31.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 16,268 shares of the company's stock worth $55,000 after acquiring an additional 3,847 shares during the last quarter. Institutional investors own 42.75% of the company's stock.

Analysts Set New Price Targets

XERS has been the topic of several recent research reports. Wall Street Zen upgraded shares of Xeris Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 9th. Oppenheimer lifted their price objective on shares of Xeris Biopharma from $6.00 to $7.00 and gave the stock an "outperform" rating in a research report on Friday, May 9th. Finally, HC Wainwright upgraded shares of Xeris Biopharma to a "buy" rating and set a $10.00 price objective on the stock in a research report on Tuesday. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $6.58.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.